Crocs Reconsidered As Value Opportunity Despite Weak Recent Share Performance

  • Crocs (NasdaqGS:CROX) has been identified as a value investment, supported by strong earnings and solid financial health.
  • The company’s current share price is $82.27, with this value case emerging as the stock trades on a relatively low valuation.
  • The reassessment of Crocs as a value opportunity is drawing attention to the gap between recent share performance and underlying business strength.

For investors, Crocs looks quite different on paper than its recent share performance might suggest. The stock is at $82.27, with returns of 13.9% over 5 years, a 20.4% decline over the past year, and a 33.2% decline over 3 years. That disconnect is part of what is putting NasdaqGS:CROX on the radar as a potential value idea, supported by a value score of 4.

Recognition of Crocs as a value name is prompting some investors to take a fresh look at the company’s earnings power and balance sheet. If you have previously written it off based on recent share price weakness, this shift in sentiment may be a cue to reassess how its current valuation aligns with your risk tolerance and time horizon.

Stay updated on the most important news stories for Crocs by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Crocs.

NasdaqGS:CROX 1-Year Stock Price Chart
NasdaqGS:CROX 1-Year Stock Price Chart

Why Crocs could be great value

Advertisement

Quick Assessment

  • ✅ Price vs Analyst Target: Crocs trades at $82.27, below the US$89.75 analyst target, with the range spanning US$71 to US$112.
  • ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading about 47.8% below its estimated fair value.
  • ❌ Recent Momentum: The 30 day return is about 7.9% lower, signaling weak short term sentiment despite the value case.

Check out Simply Wall St's in depth valuation analysis for Crocs.

Key Considerations

  • 📊 The value angle rests on strong earnings, solid financial health and a share price that sits below both the analyst target and the estimated fair value.
  • 📊 Watch the P/E of 23.4 versus the luxury industry average of 19.6, the forward P/E of 9.5 and any updates to earnings or free cash flow that support the valuation case.
  • ⚠️ The most relevant risk for this news is that profit margins are 4.5%, lower than last year’s 20.5%, alongside a high level of debt.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Crocs analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:CROX

Crocs

Designs, develops, manufactures, markets, distributes, and sells casual lifestyle footwear and accessories for men, women, and kids under the Crocs and HEYDUDE Brands in the United States and internationally.

Reasonable growth potential with adequate balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7720.1% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

FE
PASS3 logo
FernandoLeal on Compass Gas e Energia ·

Compass Gas e Energia has a reliable dividend, with a consistent moat, high free cash flow margins and will expand to two digits net margin.

Fair Value:R$40.0638.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$273.5% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
84 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
191 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0